Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Treatment of acute transverse myelitis and its early complications.
Application of fullerenes in nanomedicine: an update.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
BTG Commences Phase IIa Study of Multiple Sclerosis
Analysis: Healthy babies born after accelerated elimination of teriflunomide
The mystery of missing heritability: Genetic interactions create phantom heritability.
Stress signaling etches heritable marks on chromatin.
Embryonic stem cell lines derived from human blastocysts.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
First proof for rituximab in IgG4-related disease
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
Copolymer 1 inhibits manifestations of graft rejection.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
Idebenone for primary progressive multiple sclerosis
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.

Pages